24654-1-AP

antibody from Proteintech Group

Targeting: SLC5A2 SGLT2

Provider product page for 24654-1-AP

Western blot

ELISA

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [33]
Comments [0]
Validations [0]

Submit

Product number: 24654-1-AP - Provider product page
Provider: Proteintech Group
Proper citation: Proteintech Cat#24654-1-AP, RRID:AB_2750601
Product name: SGLT2 antibody
Antibody type: Polyclonal
Description: KD/KO validated SGLT2 antibody (Cat. #24654-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB, ELISA.
Reactivity: Human, Mouse, Rat
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 20ul, 150ul

SLC5A2 protein structure - 24654-1-AP shown in red.

Submitted references Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition.

Chen S, Overberg K, Ghouse Z, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2024 May;174:116477

SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice.

Zeng L, Li J, Gao F, Song Y, Wei L, Qu N, Chen S, Zhao X, Lei Z, Cao W, Chen L, Jiang H
Journal of cellular and molecular medicine 2024 Mar;28(6):e18176

Functional and metabolomic analysis of urinary extracellular vesicles from juvenile mice with renal compensatory hypertrophy.

Aly R, Darwish S, Bala N, Ebrahim A, Shoemaker LR, McCray J, Garrett TJ, Alli AA
Biochimica et biophysica acta. Molecular basis of disease 2024 Jun;1870(5):167096

Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels.

Cai A, Shen J, Yang X, Shao X, Gu L, Mou S, Che X
Frontiers in immunology 2023;14:1205834

Canagliflozin alleviates high glucose-induced peritoneal fibrosis via HIF-1α inhibition.

Wang J, Lv X, A-Ni-Wan AS, Tian SS, Wang JM, Liu HY, Fan XG, Zhou SJ, Yu P
Frontiers in pharmacology 2023;14:1152611

Adrenal SGLT1 or SGLT2 as predictors of atherosclerosis under chronic stress based on a computer algorithm.

Li J, Meng L, Wu D, Xu H, Hu X, Hu G, Chen Y, Xu J, Gong T, Liu D
PeerJ 2023;11:e15647

Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.

Shoda K, Tsuji S, Nakamura S, Egashira Y, Enomoto Y, Nakayama N, Shimazawa M, Iwama T, Hara H
Cellular and molecular neurobiology 2023 Mar;43(2):879-892

PCK1 is a key regulator of metabolic and mitochondrial functions in renal tubular cells.

Verissimo T, Dalga D, Arnoux G, Sakhi I, Faivre A, Auwerx H, Bourgeois S, Paolucci D, Gex Q, Rutkowski JM, Legouis D, Wagner CA, Hall AM, de Seigneux S
American journal of physiology. Renal physiology 2023 Jun 1;324(6):F532-F543

Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.

Ding L, Chen X, Zhang W, Dai X, Guo H, Pan X, Xu Y, Feng J, Yuan M, Gao X, Wang J, Xu X, Li S, Wu H, Cao J, He Q, Yang B
The Journal of clinical investigation 2023 Jan 3;133(1)

Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.

Chen S, Wang Q, Christodoulou A, Mylonas N, Bakker D, Nederlof R, Hollmann MW, Weber NC, Coronel R, Wakker V, Christoffels VM, Andreadou I, Zuurbier CJ
Circulation 2023 Jan 17;147(3):276-279

Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2.

Wu Q, Yao Q, Hu T, Yu J, Jiang K, Wan Y, Tang Q
Cell reports. Medicine 2023 Dec 19;4(12):101334

Diacylated anthocyanins from purple sweet potato (Ipomoeabatatas L.) attenuate hyperglycemia and hyperuricemia in mice induced by a high-fructose/high-fat diet.

Shen L, Yang Y, Zhang J, Feng L, Zhou Q
Journal of Zhejiang University. Science. B 2023 Apr 15;24(7):587-601

SGLT1/2 as the potential biomarkers of renal damage under Apoe(-/-) and chronic stress via the BP neural network model and support vector machine.

Hu GF, Wang X, Meng LB, Li JY, Xu HX, Wu DS, Shan MJ, Chen YH, Xu JP, Gong T, Chen Z, Li YJ, Liu DP
Frontiers in cardiovascular medicine 2022;9:948909

Renal oncometabolite L-2-hydroxyglutarate imposes a block in kidney tubulogenesis: Evidence for an epigenetic basis for the L-2HG-induced impairment of differentiation.

Taub M, Mahmoudzadeh NH, Tennessen JM, Sudarshan S
Frontiers in endocrinology 2022;13:932286

SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis.

Long Q, Li L, Yang H, Lu Y, Yang H, Zhu Y, Tang Y, Liu C, Yuan J
International immunopharmacology 2022 Sep;110:109024

Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes.

Marfella R, Scisciola L, D'Onofrio N, Maiello C, Trotta MC, Sardu C, Panarese I, Ferraraccio F, Capuano A, Barbieri M, Balestrieri ML, Napoli C, Paolisso G
Pharmacological research 2022 Oct;184:106448

USP22-mediated deubiquitination of PTEN inhibits pancreatic cancer progression by inducing p21 expression.

Ren D, Sun Y, Li D, Wu H, Jin X
Molecular oncology 2022 Mar;16(5):1200-1217

A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.

Liu W, Ren D, Xiong W, Jin X, Zhu L
Journal of experimental & clinical cancer research : CR 2022 Jan 26;41(1):38

Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK/mTOR mediated autophagy pathway.

Yang L, Liang B, Li J, Zhang X, Chen H, Sun J, Zhang Z
Cellular signalling 2022 Feb;90:110206

Hepatic expression of sodium-glucose cotransporter 2 (SGLT2) in patients with chronic liver disease.

Nakano D, Akiba J, Tsutsumi T, Kawaguchi M, Yoshida T, Koga H, Kawaguchi T
Medical molecular morphology 2022 Dec;55(4):304-315

Renal denervation ameliorates cardiac metabolic remodeling in diabetic cardiomyopathy rats by suppressing renal SGLT2 expression.

Huo JY, Jiang WY, Zhang SG, Lyu YT, Geng J, Chen M, Chen YY, Jiang ZX, Shan QJ
Laboratory investigation; a journal of technical methods and pathology 2022 Apr;102(4):341-351

High-Salt Attenuates the Efficacy of Dapagliflozin in Tubular Protection by Impairing Fatty Acid Metabolism in Diabetic Kidney Disease.

Zou M, Chen Y, Zheng Z, Sheng S, Jia Y, Wang X, Ren S, Yang Y, Li X, Dong W, Guan M, Zhang Q, Xue Y
Frontiers in pharmacology 2021;12:741087

SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis.

Ren D, Sun Y, Zhang D, Li D, Liu Z, Jin X, Wu H
Cancer letters 2021 Oct 28;519:277-288

Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease.

Wang D, Zhang Z, Si Z, Yang Y, Li S, Xue Y
FEBS open bio 2021 May;11(5):1395-1405

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.

D'Onofrio N, Sardu C, Trotta MC, Scisciola L, Turriziani F, Ferraraccio F, Panarese I, Petrella L, Fanelli M, Modugno P, Massetti M, Marfella LV, Sasso FC, Rizzo MR, Barbieri M, Furbatto F, Minicucci F, Mauro C, Federici M, Balestrieri ML, Paolisso G, Marfella R
Molecular metabolism 2021 Dec;54:101337

Redefining the Role of ADAM17 in Renal Proximal Tubular Cells and Its Implications in an Obese Mouse Model of Pre-Diabetes.

Palau V, Villanueva S, Jarrín J, Benito D, Márquez E, Rodríguez E, Soler MJ, Oliveras A, Gimeno J, Sans L, Crespo M, Pascual J, Barrios C, Riera M
International journal of molecular sciences 2021 Dec 3;22(23)

Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).

Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T
PloS one 2020;15(4):e0232283

Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha.

Ndibalema AR, Kabuye D, Wen S, Li L, Li X, Fan Q
Diabetes, metabolic syndrome and obesity : targets and therapy 2020;13:1953-1967

Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro.

Li T, Fang T, Xu L, Liu X, Li X, Xue M, Yu X, Sun B, Chen L
Frontiers in pharmacology 2020;11:622153

Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.

Zhou J, Zhu J, Yu SJ, Ma HL, Chen J, Ding XF, Chen G, Liang Y, Zhang Q
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020 Dec;132:110821

Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy.

Otomo H, Nara M, Kato S, Shimizu T, Suganuma Y, Sato T, Morii T, Yamada Y, Fujita H
Metabolism: clinical and experimental 2020 Dec;113:154405

High Glucose Triggers Nucleotide Imbalance through O-GlcNAcylation of Key Enzymes and Induces KRAS Mutation in Pancreatic Cells.

Hu CM, Tien SC, Hsieh PK, Jeng YM, Chang MC, Chang YT, Chen YJ, Chen YJ, Lee EYP, Lee WH
Cell metabolism 2019 Jun 4;29(6):1334-1349.e10

Suppressive effects of the sodium‑glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice.

Kato J, Shirakami Y, Ohnishi M, Mizutani T, Kubota M, Sakai H, Ibuka T, Tanaka T, Shimizu M
Oncology reports 2019 Dec;42(6):2797-2805

No comments: Submit comment

No validations: Submit validation data